Conceptio
›
Archive
›
ClinicalTrials.gov
ClinicalTrials.gov
public full text
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Peking Union Medical College Hospital
· 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
cervical cancer recurrent, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
#1033716
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
#1033723
The Effect of Nicorandil on Rheumatoid Arthritis Patients
#1033725
Acupuncture for Heel Pain Syndrome
#1033717
A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
#1033719
Record
· ID 883660
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.